SCHEDULE 13G/A: Rock Springs Capital Fully Divests Stake in Xilio Therapeutics, Reporting 0% Ownership

Sentiment:

Beneficial Ownership Change 15 May 2025 2:48 PM

📋All filings for Xilio Therapeutics, INC

Rock Springs Capital Management LP and its affiliated entities have filed an amended Schedule 13G, indicating a complete divestment of their beneficial ownership in Xilio Therapeutics, Inc., now holding 0% of the common stock.

Worse than expectedThe document indicates a complete divestment of shares by Rock Springs Capital Management LP and its affiliates, reducing their beneficial ownership to 0%. This full exit by an institutional investor is generally perceived as a negative signal for the company's stock.

Summary

Rock Springs Capital Management LP, Rock Springs Capital LLC, Rock Springs Capital Master Fund LP, Mark Bussard, and Kris Jenner (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
The filing indicates that as of March 31, 2025, the Reporting Persons beneficially own 0.00 shares of Xilio Therapeutics, Inc. common stock.
This represents 0% of the class of securities, signifying a complete divestment of their previous holdings.
The Reporting Persons confirm that the securities were not acquired and are not held for the purpose of changing or influencing the control of Xilio Therapeutics, Inc.

Sentiment

Score: 2

Explanation: The sentiment is negative due to the complete divestment of shares by a significant institutional investor, which typically signals a lack of confidence or a bearish outlook on the company's future prospects.

Negatives

The complete divestment by Rock Springs Capital Management LP and its affiliates suggests a loss of confidence or a change in investment strategy regarding Xilio Therapeutics, Inc.
A full exit by an institutional investor can be perceived negatively by the market and may put downward pressure on the stock price.

Future Outlook

The document does not provide any forward-looking statements or guidance from Xilio Therapeutics, Inc. or the Reporting Persons regarding the issuer's future performance.

Industry Context

This filing reflects a common occurrence in the investment landscape where institutional investors adjust their portfolios based on their assessment of a company's prospects, market conditions, or their own strategic objectives. A complete divestment, especially from a significant holder, can sometimes signal a shift in broader investor sentiment within the biotech or pharmaceutical sector, though this specific filing does not provide reasons for the divestment.

Stakeholder Impact

Shareholders: The complete divestment by an institutional investor could lead to negative market sentiment and potential downward pressure on Xilio Therapeutics' share price, impacting existing shareholders.

Key Dates

Date	Description
03/31/2025	Date of event which requires the filing of this statement, indicating the effective date of the ownership change.
05/15/2025	Date the Schedule 13G Amendment No. 3 was signed and filed.

Recommendation

sell

Keywords

Xilio Therapeutics, Rock Springs Capital, Schedule 13G, Beneficial Ownership, Divestment, Institutional Investor, Common Stock, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.